Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (11632)	11/25/1997 6:29:00 AM
From: Henry Niman	Respond to of 32384

Andy, The Ron Evan's summary described basic research on formation of heterodimers and their regulation. RXRs (activated by Targretin and other rexinoids) serve as partners for a wide variety of receptors. The summary mentioned a few of them, including steroid hormone receptors (which is what LLY is focusing on with Evista, Raloxifene), which acts as an agonist for the estrogen receptor). The report also described a receptor activated by malvolonic acid metabolits. Malvolonic acid is a precursor for many of the hormones which activate IRs.